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184 Evaluation of the impact of SERPINA gene mutation on the
occurrence of liver damage and cholestasis in patients diagnosed
with cystic ﬁbrosis
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1Medical University of Silesia, Department of Paediatrics, Katowice, Poland
SERPINA1 gene is present in about 2% of patients with cystic ﬁbrosis, but
more frequently, in approximately 5% of patients with cystic ﬁbrosis (CF) and
concomitant changes in the liver.
Aim: The aim of this study was to assess the impact of SERPINA gene mutation
on the occurrence of liver damage and cholestasis in patients diagnosed with cystic
ﬁbrosis.
Patients and Methods: The analysis included 30 children, 13 girls (43.3%) and
17 boys (56.6%), aged from 6 months to 18 years, with diagnosed CF. All patients
underwent genetic testing for SERPINA gene mutation. The analysis included
age, sex, clinical symptoms, type of mutation of the CFTR protein, laboratory
abnormalities (levels of transaminases, GGTP, FA, protein, acid steatocrit) and
ultrasound examination of the abdomen.
Results: Elevated transaminases were found in 9/30 (30%), whereas elevated
levels of gamma-glutamyl transferase in 6/30 (20%) children. In 5/30 patients the
ultrasound examination demonstrated liver enlargement with increased echogenicity.
The mutation in SERPINA gene was found in 1/30 (3.3%) patient with cystic
ﬁbrosis. Currently, this patient has normal values of transaminases, GGTP and FA,
whereas, a signiﬁcant worsening of respiratory symptoms is observed. There was
no correlation between the occurrence of SERPINA gene mutation and clinical
symptoms, type of CFTR protein mutation, results of laboratory tests of liver
function and hepatocyte damage, and ultrasound examination of the abdomen.
Conclusions: There was no correlation between the occurrence of SERPINA gene
mutation and the presence of features of liver damage and cholestasis in children
diagnosed with cystic ﬁbrosis.
185 Transient elastography measurements in adults with cystic
ﬁbrosis liver disease
G.H. Jones1, P. Richardson2, M. Ledson1, M. Walshaw1, J. Greenwood1.
1Liverpool Heart & Chest Hospital, Adult CF Service, Liverpool, United
Kingdom; 2Royal Liverpool & Broadgreen University Hospitals, Hepatology,
Liverpool, United Kingdom
Objectives: Liver disease causes an increase in its stiffness and although this can
be measured by transient elastography (TE), the utility of this simple test in adult
CF-related liver disease (CFLD) has not been established. We report the use of TE
to assess CFLD in the largest series of adult CF patients to date.
Methods: Using a Fibroscan® 402, TE was measured by taking the median value
from at least 10 readings. The diagnosis of CFLD in individual patients was
conﬁrmed from blood, ultrasound and endoscopy results.
Results: Of 139 consecutive patients studied (mean age 27.3 [range 17−55], 85
male), valid readings were obtained in 136 (98%) but 4 patients had incomplete
datasets. TE (in kPa) of the 22 with CFLD was higher than the remainder (median
11.1 [IQR 8.3–13.7] versus 4.3 [3.5−5.4], p< 0.001). TE was a highly accurate
test for predicting CFLD (area under receiver operating curve = 0.95): a value
<6.6 kPa effectively excluded the diagnosis (99% negative predictive value, negative
likelihood ratio 0.05) whilst those >7.6 kPa were at least 30 times more likely to
have liver disease.
Mean
age
% Male Mean
FEV1 %
CFRD Median TE (IQR)
CFLD (n = 22) 26.0 77.3% 64.5% 50.0% 11.1 kPa (8.3–13.7)
No CFLD (n = 110) 27.5 59.1% 65.9% 68.2% 4.3 kPa (3.5−5.4)
Conclusion: In this, the largest series of its kind, we have shown that TE, a simple
non-invasive test, can be performed during routine outpatient review, and is a highly
accurate predictor of CFLD in adult CF patients.
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Objectives: The optimal frequency of ultrasound scans (USS) to monitor the
development of portal hypertension (PH) in CF-related liver disease (CFLD) is
unknown. Transient elastography (TE), a simple non-invasive form of monitoring,
is being increasingly used as an alternative to USS but there is little experience in
adult CF.
Methods: Using a Fibroscan® 402 device, we compared the utility of TE with
USS in the diagnosis of PH. TE was measured using the median value from at least
10 readings at routine outpatient review. The most recent USS was reviewed and
considered abnormal if it featured heterogeneous or nodular changes or signs of
portal hypertension.
Results: TE was compared with contemporaneous USS in 78 patients (mean age
26.8, [range 17−53], male 66.7%). The 15 with an abnormal USS had a higher
TE than the remainder (median 11.7 kPa [IQR 10.0–19.6] vs 4.4 [IQR 3.7−6.3]
p< 0.005). TE was highly useful in differentiating whether abnormalities were
present on USS (area under receiver operating curve = 0.94), where a cut-off of
6.6 kPa excluded USS abnormality (98% negative predictive value). All patients
with PH on USS had a TE of 10.8 kPa. Furthermore, USS were normal in 3 with
oesophageal varices: all had raised TE.
Conclusion: TE can be used to identify CF patients likely to have changes of CFLD
on USS, and may be a better predictor of signiﬁcant disease than USS alone. Since it
is quick to administer, gives immediate results and can be measured during routine
outpatient review, TE may be a useful tool to guide which patients are referred on
for more resource intensive investigations that require specialist staff to administer
and interpret.
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Introduction: Liver disease is the second non-pulmonary cause of death in cystic
ﬁbrosis, witch, with increasing life expectancy, became an important management
problem. Predisposing factors like male sex, pancreatic insufﬁciency, meconium
ileus and severe mutation are incriminated to inﬂuence the occurrence of cystic
ﬁbrosis associated liver disease (CFLD).
Objectives: Evaluation of CFLD presence among CF patients and identiﬁcation of
its risk factors in Romanian population.
Methods: Study included 174 patients with CF, monitored in the National CF Cen-
tre. They were routinely followed-up by clinical assessment, liver biochemical tests,
ultrasound examinations and other methods like transient elastography, biopsy, in
selected cases. CFLD was diagnosed according current guidelines. A chi square
test of independence with Yates continuity correction was used to determine the
association between the risk factors and the presence of CFLD.
Results: Sixty-six patients, median age at diagnosis 4.33 years, were diagnosed
with CFLD, without signiﬁcant gender gap. CFLD was frequent in patients aged
over 8 years, with meconium ileus history, carriers of severe mutations (p = 0.002).
Pancreatic insufﬁciency, although present in 75% of patients with CFLD was not
conﬁrmed as risk factor, nor male gender, in our study.
Conclusion: CF children older than eight years of age, carriers of a severe genotype,
with a positive history of meconium ileus, were more likely predisposed to CFLD.
Further studies should discover other signiﬁcant inﬂuences in order to prevent the
development of liver cirrhosis and prolong the life of cystic ﬁbrosis children.
